Meeting
2020 Gastrointestinal Cancers Symposium
Phase Ib study to test the safety and activity of pembrolizumab (anti-PD-1) and trebananib (angiopoietin-2 inhibitor [Ang-2]) in patients with advanced solid tumors: Updated analysis of the colorectal cancer (CRC) cohort.
Authors
Osama E. Rahma
Dana-Farber Cancer Institute, Boston, MA
Osama E. Rahma , James M. Cleary , Kimmie Ng , Benjamin L. Schlechter , Jessica Eno , Anna Maloney , Anita Giobbie-Hurder , David F. McDermott , F. Stephen Hodi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03239145
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 155)
Abstract #
155
Poster Bd #
G19
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors.
First Author: Aung Naing
Poster
2020 ASCO Virtual Scientific Program
Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors.
First Author: Melissa Lynne Johnson
Poster
2019 ASCO Annual Meeting
A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors.
First Author: Matthew David Hellmann
Poster
2018 ASCO Annual Meeting
Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation.
First Author: Kathleen N. Moore